中国卒中杂志2026，Vol.21Issue(1)：88-98,11.DOI:10.3969/j.issn.1673-5765.2026.01.010
单唾液酸四己糖神经节苷脂治疗急性缺血性卒中临床应用中国专家共识
Chinese Expert Consensus on the Clinical Application of Monosialotetrahexosylganglioside in Acute Ischemic Stroke
中国卒中学会 1徐安定 2罗本燕 3徐运4
作者信息
- 2. 广州 510632 暨南大学临床神经科学研究所,暨南大学附属第一医院神经内科
- 3. 杭州 310000 浙江大学医学院附属第一医院
- 4. 南京 210000 南京大学医学院附属鼓楼医院
- 折叠
摘要
Abstract
To further standardize the application of monosialotetrahexosylganglioside(GM1)in the treatment of acute ischemic stroke(AIS),ensure medication safety,and optimize therapeutic efficacy,the Chinese Stroke Association convened a panel of experts.Based on a systematic review of the latest clinical research evidence from both domestic and international studies,and incorporating experts'clinical expertise,the panel developed the Chinese Expert Consensus on the Clinical Application of Monosialotetrahexosylganglioside in Acute Ischemic Stroke through multiple rounds of discussion and revision.This consensus systematically elaborates on the pharmacological mechanisms of GM1,focusing on four key clinical issues:the efficacy and timing of GM1 in the treatment of AIS,its safety and common adverse reactions,its effectiveness in combination with reperfusion therapy,and its application in special AIS populations.Targeted and feasible consensus recommendations have been formed accordingly.The development of this consensus aims to provide scientific reference and guidance for clinicians in China to standardize the use of GM1 in the treatment of AIS.关键词
单唾液酸四己糖神经节苷脂/急性缺血性卒中/专家共识Key words
Monosialotetrahexosylganglioside/Acute ischemic stroke/Expert consensus分类
医药卫生引用本文复制引用
中国卒中学会,徐安定,罗本燕,徐运..单唾液酸四己糖神经节苷脂治疗急性缺血性卒中临床应用中国专家共识[J].中国卒中杂志,2026,21(1):88-98,11.
